IPA (ImmunoPrecise Antibodies)

ImmunoPrecise Antibodies is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. ImmunoPrecise aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with our therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. Our discovery and development are conducted in Utrecht and Oss, the Netherlands (IPA Europe), and Victoria, British Columbia (IPA Canada) with headquarters located in Fargo, North Dakota. We operate multi-nationally to offer a continuum of antibody services, transforming the face of therapeutic discovery, by decreasing turnaround time and risk, and promoting clinical success.